Contact us

877-469-1TRM
424-208-8866

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies (RECOURSE)

Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

For more information, please visit ClinicalTrials.gov

Patient Population Investigational Product(s) Phase Status
Metastatic Colorectal Cancer – Third Line TAS-102 III Closed to Accrual